SANOFI-ADR (SNY)
US80105N1054 - ADR
We assign a fundamental rating of 6 out of 10 to SNY. SNY was compared to 194 industry peers in the Pharmaceuticals industry. While SNY belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. SNY may be a bit undervalued, certainly considering the very reasonable score on growth This makes SNY very considerable for value investing!
1. Profitability
1.1 Basic Checks
In the past year SNY was profitable.
SNY had a positive operating cash flow in the past year.
In the past 5 years SNY has always been profitable.
Each year in the past 5 years SNY had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 6.07%, SNY belongs to the best of the industry, outperforming 89.06% of the companies in the same industry.
SNY has a better Return On Equity (10.83%) than 89.06% of its industry peers.
The Return On Invested Capital of SNY (12.36%) is better than 91.15% of its industry peers.
The Average Return On Invested Capital over the past 3 years for SNY is significantly below the industry average of 42.22%.
The 3 year average ROIC (7.23%) for SNY is below the current ROIC(12.36%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.07% | ||
| ROE | 10.83% | ||
| ROIC | 12.36% |
ROA(3y)5.35%
ROA(5y)5.85%
ROE(3y)9.18%
ROE(5y)10.34%
ROIC(3y)7.23%
ROIC(5y)6.72%
1.3 Margins
SNY has a Profit Margin of 11.06%. This is amongst the best in the industry. SNY outperforms 87.50% of its industry peers.
SNY's Profit Margin has been stable in the last couple of years.
Looking at the Operating Margin, with a value of 21.92%, SNY belongs to the top of the industry, outperforming 88.02% of the companies in the same industry.
SNY's Operating Margin has improved in the last couple of years.
SNY's Gross Margin of 69.08% is fine compared to the rest of the industry. SNY outperforms 72.40% of its industry peers.
SNY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.92% | ||
| PM (TTM) | 11.06% | ||
| GM | 69.08% |
OM growth 3Y0.85%
OM growth 5Y2.94%
PM growth 3Y-29.3%
PM growth 5Y-0.74%
GM growth 3Y0.92%
GM growth 5Y0.41%
2. Health
2.1 Basic Checks
SNY has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for SNY remains at a similar level compared to 1 year ago.
The number of shares outstanding for SNY has been increased compared to 5 years ago.
SNY has a better debt/assets ratio than last year.
2.2 Solvency
SNY has an Altman-Z score of 2.84. This is not the best score and indicates that SNY is in the grey zone with still only limited risk for bankruptcy at the moment.
SNY has a Altman-Z score of 2.84. This is in the better half of the industry: SNY outperforms 70.83% of its industry peers.
The Debt to FCF ratio of SNY is 5.74, which is a neutral value as it means it would take SNY, 5.74 years of fcf income to pay off all of its debts.
SNY has a Debt to FCF ratio of 5.74. This is amongst the best in the industry. SNY outperforms 85.94% of its industry peers.
A Debt/Equity ratio of 0.20 indicates that SNY is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.20, SNY is in line with its industry, outperforming 43.75% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | 5.74 | ||
| Altman-Z | 2.84 |
ROIC/WACC1.74
WACC7.09%
2.3 Liquidity
SNY has a Current Ratio of 1.00. This is a normal value and indicates that SNY is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.00, SNY is not doing good in the industry: 84.38% of the companies in the same industry are doing better.
A Quick Ratio of 0.65 indicates that SNY may have some problems paying its short term obligations.
The Quick ratio of SNY (0.65) is worse than 89.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1 | ||
| Quick Ratio | 0.65 |
3. Growth
3.1 Past
SNY shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.59%.
The Earnings Per Share has been growing by 8.19% on average over the past years. This is quite good.
Looking at the last year, SNY shows a small growth in Revenue. The Revenue has grown by 4.26% in the last year.
SNY shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.42% yearly.
EPS 1Y (TTM)-1.59%
EPS 3Y10.81%
EPS 5Y8.19%
EPS Q2Q%12.16%
Revenue 1Y (TTM)4.26%
Revenue growth 3Y7.52%
Revenue growth 5Y5.42%
Sales Q2Q%12.32%
3.2 Future
SNY is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.98% yearly.
SNY is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.58% yearly.
EPS Next Y-4.89%
EPS Next 2Y3.65%
EPS Next 3Y5.55%
EPS Next 5Y6.98%
Revenue Next Year5.19%
Revenue Next 2Y5.93%
Revenue Next 3Y5.96%
Revenue Next 5Y5.58%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
SNY is valuated reasonably with a Price/Earnings ratio of 11.32.
SNY's Price/Earnings ratio is rather cheap when compared to the industry. SNY is cheaper than 90.63% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 28.96. SNY is valued rather cheaply when compared to this.
A Price/Forward Earnings ratio of 10.43 indicates a reasonable valuation of SNY.
Based on the Price/Forward Earnings ratio, SNY is valued cheaper than 86.46% of the companies in the same industry.
SNY's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.82.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.32 | ||
| Fwd PE | 10.43 |
4.2 Price Multiples
93.75% of the companies in the same industry are more expensive than SNY, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, SNY is valued cheaply inside the industry as 82.29% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 27.52 | ||
| EV/EBITDA | 6.5 |
4.3 Compensation for Growth
SNY has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1.38
EPS Next 2Y3.65%
EPS Next 3Y5.55%
5. Dividend
5.1 Amount
SNY has a Yearly Dividend Yield of 3.98%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 4.28, SNY pays a better dividend. On top of this SNY pays more dividend than 95.31% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.23, SNY pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.98% |
5.2 History
The dividend of SNY has a limited annual growth rate of 3.34%.
SNY has been paying a dividend for at least 10 years, so it has a reliable track record.
SNY has decreased its dividend recently.
Dividend Growth(5Y)3.34%
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
SNY pays out 59.74% of its income as dividend. This is a bit on the high side, but may be sustainable.
The dividend of SNY is growing, but earnings are growing more, so the dividend growth is sustainable.
DP59.74%
EPS Next 2Y3.65%
EPS Next 3Y5.55%
SANOFI-ADR
NASDAQ:SNY (11/21/2024, 8:00:02 PM)
After market: 47.98 0 (0%)47.98
+0.2 (+0.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap120.28B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.98% |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.32 | ||
| Fwd PE | 10.43 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)1.38
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.07% | ||
| ROE | 10.83% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 21.92% | ||
| PM (TTM) | 11.06% | ||
| GM | 69.08% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1 | ||
| Quick Ratio | 0.65 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-1.59%
EPS 3Y10.81%
EPS 5Y
EPS Q2Q%
EPS Next Y-4.89%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)4.26%
Revenue growth 3Y7.52%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y